334 related articles for article (PubMed ID: 38298195)
1. From MASH to HCC: the role of Gas6/TAM receptors.
Apostolo D; Ferreira LL; Vincenzi F; Vercellino N; Minisini R; Latini F; Ferrari B; Burlone ME; Pirisi M; Bellan M
Front Immunol; 2024; 15():1332818. PubMed ID: 38298195
[TBL] [Abstract][Full Text] [Related]
2. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
3. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
4. GAS6/TAM Axis as Therapeutic Target in Liver Diseases.
Tutusaus A; Morales A; García de Frutos P; Marí M
Semin Liver Dis; 2024 Feb; 44(1):99-114. PubMed ID: 38395061
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
Grøndal SM; Tutusaus A; Boix L; Reig M; Blø M; Hodneland L; Gausdal G; Jackson A; Garcia de Frutos P; Lorens JB; Morales A; Marí M
Front Immunol; 2024; 15():1400553. PubMed ID: 38817615
[TBL] [Abstract][Full Text] [Related]
6. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
7. Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis.
Smirne C; Rigamonti C; De Benedittis C; Sainaghi PP; Bellan M; Burlone ME; Castello LM; Avanzi GC
Dis Markers; 2019; 2019():2304931. PubMed ID: 31583026
[TBL] [Abstract][Full Text] [Related]
8. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
9. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
10. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
[TBL] [Abstract][Full Text] [Related]
11. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis antagonizing transcription factor-mediated liver damage and inflammation to cancer: Therapeutic intervention by curcumin in experimental metabolic dysfunction associated steatohepatitis-hepatocellular carcinoma.
Srinivas AN; Suresh D; Chidambaram SB; Santhekadur PK; Kumar DP
J Cell Physiol; 2024 Jan; 239(1):135-151. PubMed ID: 37942831
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors.
Hedrich V; Breitenecker K; Djerlek L; Ortmayr G; Mikulits W
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771611
[TBL] [Abstract][Full Text] [Related]
14. The Gas6/TAM System and Multiple Sclerosis.
Bellan M; Pirisi M; Sainaghi PP
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27801848
[TBL] [Abstract][Full Text] [Related]
15. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
[TBL] [Abstract][Full Text] [Related]
17. Molecular insights of Gas6/TAM in cancer development and therapy.
Wu G; Ma Z; Hu W; Wang D; Gong B; Fan C; Jiang S; Li T; Gao J; Yang Y
Cell Death Dis; 2017 Mar; 8(3):e2700. PubMed ID: 28333143
[TBL] [Abstract][Full Text] [Related]
18. Gas6 deficiency prevents liver inflammation, steatohepatitis, and fibrosis in mice.
Fourcot A; Couchie D; Chobert MN; Zafrani ES; Mavier P; Laperche Y; Brouillet A
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1043-53. PubMed ID: 21350191
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
20. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
